Search

Vaughan and Asbury’s General Ophthalmology (19th edition)

Vaughan and Asbury’s General Ophthalmology (19th edition) is the latest update of this classic ophthalmology textbook that has been around for nearly 60 years. Written by British, American and Canadian authors, this book is intended for an international readership and...

A Case-Based Guide to Eye Pain: Perspectives from Ophthalmology and Neurology

A refreshing, systematic approach to eye pain, arguably one of the most commonly presenting symptoms and one that can be fraught with diagnostic challenges and management dilemmas for the busy clinician. There is a scarcity of books covering this particular...

Atopic keratoconjunctivitis (AKC) and ocular surface squamous neoplasia (OSSN)

The authors present two cases of invasive OSSN in patients with severe AKC. Case 1 was a 73-year-old male with severe AKC and atopic eczema who developed a suspicious papillary-like limbal lesion in the left eye. He had an excisional...

Ozurdex use in noninfectious uveitis

Burkholder et al. reported the practice patterns of 45 respondents of approximately 176 surveyed members of the American Uveitis Society regarding the use of the Ozurdex implant. Most respondents performed the injection in either a procedure (41.0%) or clinic (23.1%)...

IAC vs. IVC chemotherapy for RB

This a single centre retrospective review of consecutive patients between 1997 and 2014, of all sporadic unilateral retinoblastoma (RB) group D cases, treated with combined intravenous chemotherapy (IVC) and focal treatments (1997- 2008), or intra-arterial chemotherapy (IAC) treatment (2008 to...

Adjunctive topical 5-FU vs. MMC for surgically excised, localised OSSN

Ocular surface squamous neoplasia (OSSN) comprises a range of dysplasia including corneal-conjunctival intraepithelial neoplasia and invasive squamous cell carcinoma. The traditional treatment for localised non-invasive OSSN has been surgical excision with or without intraoperative cryotherapy. Postoperative adjunctive topical chemotherapy significantly...

Uveitis in HIV infected persons

Before the advent of highly active antiretroviral therapy (HAART), uveitis, in particular cytomegalovirus (CMV) retinitis, was the most common cause of visual loss in patients with AIDS. HAART has altered the cause of ocular disease in HIV infected individuals by...

Low dose steroids for ocular dry eye disease in graft vs. host disease

This double-masked randomised clinical trial compared the response of dry eye disease (DED) to treatment with topical steroids in patients with and without graft vs. host disease (GVHD). Forty-two patients in a single centre (n=21 with and n=21 without GVHD)...

Ptosis procedure compared to upper blepharoplasty on dry eye syndrome

In this prospective, comparative case series, the authors compare the effect of combined blepharoplasty and Muller muscle conjunctival resection (MMCR) to an upper blepharoplasty in dry eye syndrome. The study was approved by the local institutional review board and participants...

CHARGE syndrome features

CHARGE syndrome (CS) includes coloboma, heart defects, atresia of the choanae, retardation of growth and development, genital and urinary anomalies and ear anomalies. The authors developed an original self-administered questionnaire (VISIOcharge) for patients with CS and used it to evaluate...

Risk factors identified for glaucoma progression in paediatric glaucoma suspects

A retrospective case review was conducted of children (<18 years) identified as being glaucoma suspects using common clinical criteria or the Childhood Glaucoma Research Network definition. Exclusion criteria included penetrating ocular trauma, treated ocular hypertension / glaucoma and use of...

The use of adalimumab for relapse in patients with Vogt-Koyanagi-Harada disease

In this retrospective, multi-centre, cohort study, the efficacy and safety of Adalimumab (ADA) treatment for the exacerbation or recurrence of Vogt-Koyanagi-Harada (VKH) patients was assessed by investigating the medical records of patients who had received ADA treatment for more than...